Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Medtronic outperforms Valneva in revenue, profitability, and stability despite Valneva's higher upside potential.
MDT
$80.48
+$0.01 +0.01%

Medtronic outperforms Valneva in revenue, profitability, and stability despite Valneva's higher upside potential.

Analyst Insights
23 Mar 2026
Defense World
View Source
Neutral
pluang ai news

Medtronic and Valneva, both medical companies, were compared on financial and operational metrics. Medtronic leads with $33.54 billion revenue, positive net income, and lower stock volatility, while Valneva shows a smaller revenue base, net losses, and higher volatility. Analysts favor Valneva for its higher potential upside (45.35%) versus Medtronic's 28.34%, but Medtronic dominates in profitability, institutional ownership, and risk management. This contrast highlights Medtronic as a stable, profitable choice and Valneva as a riskier, growth-oriented option.

More News (MDT)

Global blood glucose monitoring market to nearly double to $39.4B by 2035 with 8.9% CAGR driven by AI and home care trends

Global blood glucose monitoring market to nearly double to $39.4B by 2035 with 8.9% CAGR driven by AI and home care trends

The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...

Market News
Bullish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App